Humanized monoclonal antibody (anti-IL-26) for Psoriasis
Psoriasis, a chronic skin disease / condition, characterized by red, itchy scaly patches most commonly on the knees, elbows, trunk and scalp.
Interleukin 26 (IL-26) has recently been found to be overexpressed in certain psoriasis forms.
IL-26 concentrations in healthy skin and psoriatic skin lesions measured by ELISA of total skin extracts derived from healthy donors (n = 15) or psoriasis patients (n = 15). Each data point represents an individual donor. (Meller et al 2015, Nature immunology. V 16. p970)
Therapeutic antibodies against cytokines known to be involved in these autoimmune diseases.
Preclinical animal models have demonstrated a proof-of-concept of AVVA’s anti-IL-26 antibody, a new promising therapeutic approach that warrants further research and development.
Effect of an anti-IL-26 antibody (clone 84) on epidermal thickness in tape stripping model of psoriasis in mice overexpressing IL-26
Inventors
Michel Gilliet, MD
Professor and Chairman
Head of Immuno-dermatology Research
Department of Dermatology
CHUV University Hospital and University of Lausanne
Jeremy Di Domizio, PhD
Senior Scientist and Research Lab Supervisor
Department of Dermatology
CHUV University Hospital and University of Lausanne